Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 3Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Leukemia, Myeloid, Chronic-Phase 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Leukemia 3Squamous Cell Carcinoma of Head and Neck 1Meningioma 1Lung Neoplasms 1Leukemia, Promyelocytic, Acute 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Head and Neck Neoplasms 1Glioma 1Glioblastoma 1Esophageal Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

Radiotherapy 19Temozolomide 11Cisplatin 9Vincristine 8Chemotherapy, Adjuvant 8Carboplatin 8Etoposide 6Lomustine 5Methotrexate 4Thiotepa 3Peripheral Blood Stem Cell Transplantation 3Magnetic Resonance Spectroscopy 3Ifosfamide 3Filgrastim 3Cyclophosphamide 3Carmustine 3pegfilgrastim 2Tamoxifen 2Surgical Procedures, Operative 2Psychiatric Rehabilitation 2Pemetrexed 2Mental Status and Dementia Tests 2Hyperbaric Oxygenation 2Ethanol 2Erlotinib Hydrochloride 2Dexamethasone 2Amplified Fragment Length Polymorphism Analysis 2nedaplatin 1motexafin gadolinium 1lonafarnib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Central Nervous System Neoplasms × Hydroxyurea × Clear all
NCT00904735 2013-08-12

Hydroxyurea With or Without Imatinib Mesylate in Treating Patients With Recurrent or Progressive Meningioma

National Cancer Institute (NCI)

Phase 2 Unknown
76 enrolled
CNS

Brain Neoplasms, Meningioma, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡